All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for KYVERNA THERAPEUTICS, INC. · Biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

Lobbying activity 1

Health Issues

Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.